Hemagglutinin and innate immune receptors (HA/PRR)

Hemagglutinin (HA) is a major surface glycoprotein of the influenza virus, essential for viral attachment to host cell sialic acid receptors and subsequent membrane fusion [1]. Innate immune receptors, such as Toll-like receptors (TLRs), are host proteins that recognize pathogen-associated molecular patterns (PAMPs) to initiate an early immune response [2]. The phrase "no defined direct drug-like binding" typically refers to the interaction of vaccines or complex biologicals that do not follow traditional small-molecule pharmacology [3]. Instead of binding to a specific pocket to inhibit an enzyme, these agents often work by presenting HA as an antigen to the adaptive immune system while simultaneously stimulating innate immune receptors to enhance the overall response [4]. This dual targeting is the cornerstone of modern vaccinology, particularly for seasonal and pandemic influenza prevention [5]. [1] UniProt Consortium, "Hemagglutinin," UniProtKB P03435. [2] Li, D., et al. (2021), "Pattern recognition receptors in health and diseases," Signal Transduction and Targeted Therapy. [3] ChEMBL Database, "Target Classification." [4] Pulendran, B., & Ahmed, R. (2011), "Immunological mechanisms of vaccination," Nature Immunology. [5] CDC, "How Influenza Vaccines Work," 2023.

Other names

Influenza hemagglutininPattern recognition receptorsPRRsViral hemagglutininToll-like receptorsTLRsHemagglutinin and innate immune receptors – no defined direct drug-like binding

Induction of neutralizing antibodies against hemagglutinin to block viral entry and activation of innate immune receptors to provide costimulatory signals for adaptive immunity.